• PlantX just acquitted a 53.5% stake at Eh Coffee and a 51% stake at Portfolio Coffee Inc.
• The acquisition marks PlantX’s addition of coffee to its line of over 5,000 plant-based products
• PlantX will push products from these two companies on its e-commerce platform and physical XMarket stores

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) just announced the acquisition of a majority equity interest in Eh Coffee Corp. and Portfolio Coffee Inc. for a share consideration of 913,320 PlantX shares and a cash consideration of $434,058.14. This leaves PlantX with a 53.5% and 51% stake at Eh Coffee and Portfolio, respectively. Additionally, the company now holds three out of five board seats at each company (https://ibn.fm/cBK7a). Eh Coffee and Portfolio Coffee, founded by Jacob Fortier, Victor Nucci, and Andre Dalben, have made a name for themselves as entities that offer an industry-leading farm-to-cup coffee experience. Eh Coffee, headquartered in Toronto, Ontario, sources specialty coffee beans from key family farms worldwide and custom roasts them in Canada. On the other hand, Portfolio distributes these specialty coffees featuring different flavor profiles, roasts, and regions. Its direct trade approach empowers local farmers, and its direct-to-consumer green, sustainable packaging reflects the company’s commitment to sustainability and environmental conservation. PlantX has expressed its enthusiasm with these acquisitions. They present an opportunity for the company to grow its product line, which comprises over 5,000 plant-based products. “We are delighted to welcome the Eh Coffee and Portfolio Coffee teams to the fold of the PlantX family. Coffee is perhaps the most widely accepted plant-based product- and a universal drink to start our days. We are beyond thrilled to join together our teams to launch the Portfolio Coffee offerings roasted right here in Canada for a farm to cup experience of premium specialty coffees on the PlantX website, XMarket stores and future cafes,” noted Lorne Rapkin, the Chief Executive Officer (“CEO”) of PlantX. PlantX plans to sell products from these two companies on its online platform and its physical locations. Additionally, featuring the Portfolio brand at the XMarket Cafes will allow PlantX to offer same-day delivery within Tel Aviv, Toronto, Ottawa, Los Angeles, San Diego, and Vancouver. The company also plans to leverage its e-commerce knowledge and distribution experience to bring Portfolio’s e-commerce subscription to new heights. Eh Coffee and Portfolio’s existing management teams will remain involved in day-to-day operations and the companies’ business going forward. The addition of the founders to PlantX’s top-level management adds to its human resource’s wealth of experience and industry know-how. Portfolio, alone, for instance, has an executive team with over 20 years of experience working with award-winning farms through the global coffee supply chain, roasting and retailing specialty coffees. “We are very excited to join the PlantX team and bring the joys of coffee drinking and connoisseurship to XMarket stores and PlantX consumers. We believe that curated farm-to-cup specialty coffee from renowned crop growing regions is the sustainable path of the future for specialty coffee,” noted Eh Coffee and Portfolio founders collectively. The purchase agreement for the Eh Coffee and Portfolio acquisition provides that PlantX will have the option to purchase up to all the remaining shares on the two companies over the course of three calendar years following the closing of the transaction. All the PlantX shares issued thus far and to be issued in connection to the transaction are expected to be, upon issuance, subject to a restrictive hold period of four months and one day. PlantX hopes this new chapter of growth will add to its value, market reach, and overall brand equity. In addition, this move aligns with PlantX’s expansion strategy, particularly since the company also has plans to include cosmetics, clothing, and its own water brand. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions
• The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets
• The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform
• Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency

In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in oral nicotine, heart disease, and antiviral research. Lexaria plans to take the findings from these 2021 studies and improve them with the 2022 R&D programs, which include hormone replacement, dementia, diabetes, and rheumatoid disease (https://ibn.fm/8H7tm). While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, noted, “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension, and separately, for oral nicotine delivery as an alternative to smoking.” “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added. Lexaria announced a fraction of their 2022 applied R&D programs, among them HOR-A22-1, DEM-A22-1, RHEUM-A22-1, and DIAB-A22-1. HOR-A22-1, slated for April 2022, will be a hormone replacement study. It will evaluate the ability of Lexaria’s patented DehydraTECH to enhance estrogen among patients, allowing for the control of the menstrual cycle, cholesterol, and the protection of bone health. Through this study, Lexaria plans to capitalize on the hormone replacement market, which is estimated to grow to $46.5 billion by 2027. DEM-A22-1, scheduled for July 2022, will explore the efficiency of DehydraTECH-CBD, with and without nicotine, for the potential treatment of dementia. Once again, Lexaria plans to capitalize on the dementia drug market, which is estimated to grow to $19.6 billion by 2026. RHEUM-A22-1, scheduled for October 2022, will focus on rheumatoid disease treatment through the use of DehydraTECH-CBD. Through this study, Lexaria intends to take advantage of the growing Rheumatoid Arthritis Therapeutics market, which is projected to be valued at $30 billion by 2025. DIAB-A22-1, which is slated for November 2022, will evaluate the ability of DehydraTECH-CBD to potentially affect the treatment of diabetes. Studies so far have shown that CBD can reduce the incidence of diabetes in mice, a significant milestone in the study. Improving on these findings, Lexaria is strategically evaluating the prescription drug market used to treat diabetes, an industry expected to be valued at $77.9 billion by 2024. In addition to these studies, Lexaria also announced that it would be conducting pharmacokinetic (“PK”) and efficacy modeling studies in animals to evaluate DehydraTECH’s ability to improve the delivery characteristics of various other drugs or active pharmaceutical ingredients (“APIs”). The goal would be to identify whether there could be a commercial benefit to continue further studies and pursuit within different market sectors. Lexaria has been vocal about its R&D initiatives and endeavors. Additionally, it has remained true to its objective to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. The 2022 work programs are the company’s next biggest undertakings, and they stay true to what it stands for, along with its commitment to its stakeholders. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028
• The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth
• Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives

According to a recent Reports and Data release, the global consumer monitoring (“CGM”) devices global market is forecast to see notable growth in the coming years (https://ibn.fm/LhWNO). Key companies operating in the space, including Nemaura Medical (NASDAQ: NMRD), are ideally positioned to benefit from that growth as they work to meet the needs of the industry. The increasing prevalence of diabetes and rising focus on preventive care are major factors in the steady revenue growth projected for the CGM devices market, according to the latest analysis by Reports and Data. “The global continuous glucose monitoring devices market size was USD 4.11 billion in 2020 and is expected to reach USD 19.04 billion in 2028 and register a revenue CAGR of 19.2% during the forecast period, 2021–2028,” the article stated. “Continuous glucose monitoring devices enables tracking of blood glucose levels round the clock,” the article continued. “These devices monitor a patient’s glucose levels via sensors that send readings to the receiver’s device screen or smartphone. Continuous glucose monitoring devices aid patients in managing diabetes with lesser fingerstick tests. Increasing prevalence of diabetes in countries across the globe and growing preference for monitoring and managing diabetes at home are boosting adoption of continuous glucose monitoring devices. In addition, rapid technological advancements in glucose monitoring devices and increasing affordability of innovative devices are some other factors expected to contribute to revenue growth of the market going ahead.” The report also noted that wearable CGM devices can help patients track and understand how their sugar levels change over time. The devices also provide alerts when glucose levels reach levels fall below or rise above acceptable levels. In addition, “CGM data can provide healthcare providers critical insights into patterns of high and low glucose levels, in turn, leading to a personalized care approach and better management of diabetes. These advantages are further boosting adoption of these devices and are expected to fuel revenue growth of the market over the forecast period.” Nemaura Medical’s proprietary sugarBEAT(R) device is the world’s first-of-its-kind noninvasive continuous glucose monitoring sensor designed for use by “everyone,” meaning people dealing with either type 1 or type 2 diabetes as well as those with prediabetes. The device attaches on (not under) the skin and measures real-time blood glucose levels every five minutes. Using that data, users can track their highs and lows, identify trends, and monitor their Time in Range (TIR). This invaluable information allows individuals to make adjustments to their diet and activity that can significantly change their lives. Nemaura Medical evolved from a micro-system-based drug-delivery platform in 2011. Since then, the company has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and healthcare observation procedures. Nemaura’s BEAT(R) technology allows for continuous remote monitoring of chronic diseases and health conditions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• HENC subsidiary evaluating, pursuing property acquisitions; beginning process to obtain cultivation, sales licenses
• Sales have doubled in the past year, according to state’s seed-to-sale tracking system
• HENC working with top cannabis law firm to spearhead the process

With Massachusetts reporting marijuana sales reaching $2 billion since the state approved the adult-use market (https://ibn.fm/S8IvV), savvy cannabis companies operating in the state are looking to leverage opportunity for growth. Earlier this year, Hero Technologies (OTC: HENC), a cannabis company pursuing a vertically integrated model, announced a new subsidiary: MassCannabis LLC. The newly formed company is evaluating and pursuing property acquisitions and beginning the process to obtain licenses in Massachusetts (https://ibn.fm/XpF9F). The Cannabis Control Commission in Massachusetts has reported that gross sales from the state’s 165 cannabis retailers and three delivery services reached $2,009,007,478 as of August 31, 2021. “That doubles the sales total that the commission reported last November, according to the state’s seed-to-sale tracking system,” the report noted. “This milestone speaks to the success of licensees that have interacted with the Commission from the application stage, maintained compliance with our strict regulations, and contribute every day to communities across the Commonwealth.” In March 2021, HENC announced that it had retained a top cannabis law firm, Vincente Sederberg LLP, “to spearhead the process to obtain cannabis licenses in Massachusetts, a rapidly growing cannabis market with over $1 billion in retail sales since 2019. Vincente Sederberg is a leading advocate for the cannabis industry, with over a decade of experience in cannabis law,” the company stated. “Rolling Stone” magazine has called Vincente Sederberg a “powerhouse marijuana law firm.” “Hero Technologies’ newly formed subsidiary, MassCannabis LLC, will work closely with Sederberg to target property acquisitions and begin the process to obtain licenses to cultivate and retail cannabis in Massachusetts,” the company noted. “We are very excited about our momentum in Massachusetts,” said Hero Technologies CEO Gina Serkasevich. “Having Vincente Sederberg join forces with our new MassCannabis subsidiary should enable us to quickly identify new strategic partners and streamline the acquisition process. We look forward to reporting more developments to our shareholders as we continue to expand and integrate cannabis initiatives across geographical markets.” For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• SRAX will publish its third quarter quarterly results on Monday 15th November
• The company will also hold an investor earnings call alongside the results release, led by SRAX CEO, Christopher Miglino and CFO, Michael Malone
• Following their second quarter results, the company upped its 3Q revenue guidance to $8.3 million, representing a +7.7% quarter-on-quarter crisis
• SRAX have also recently revealed their attendance at the Ladenburg Thalmann Virtual Technology Expo, which will be held on their Sequire platform on November 18th, 2021

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has revealed that it will publish its third quarter 2021 results on Monday, November 15th (https://ibn.fm/gLEuN). On the day, SRAX’s Founder and CEO, Christopher Miglino, and CFO, Michael Malone, will provide an operational and financial summary of Q3 2021 on a video call, featuring a live question and answer session, to be held at 4:30 pm ET / 1:30pm PT. To register for the live webcast and view the presentation, investors will be able to sign up at the following link: (https://ibn.fm/BH6i4). SRAX has seen its financial returns enjoy a remarkable rise over the past year. For the second quarter of fiscal 2021, the company reported Q2 revenues of $7.7 million, up 557% year-over-year, and rising by 41% quarter-on-quarter. The company also seized on the opportunity to update their corporate revenue guidance, increasing Q3 revenue guidance to $8.3 million, which would represent at least a +7.7% quarter-on-quarter increase. SRAX also increased their full year revenue target to $32 million, up from $30 million previously (https://ibn.fm/uWMli). Immediately following their second quarter earnings report, SRAX announced that they would be carrying out a simultaneous $10 million stock buy-back program as well as paying a one-time special dividend to its shareholders of records as of the 20th of September 2021. The special dividend, which would bear an approximate value of $0.23 per common share, would be in the form of an issuance of non-tradeable preferred shares, which would hold a notional value of approximately $6.5 million worth of Sequire’s clients’ stock. As the underlying shares are sold, the proceeds will be distributed to the preferred shareholders on a periodic basis. In addition to their upcoming quarterly earnings results announcement, SRAX has also recently announced that the company will be presenting at the Ladenburg Thalmann Virtual Technology Expo, a one-day investor event featuring major technology companies, on November 18th. The event, which is being hosted on the Sequire virtual conferencing platform, will feature presentations from the management of approximately 50 technology companies from the US and Israel, covering a diverse array of sectors, including connectivity, cloud and enterprise software, cybersecurity, streaming, semiconductors and cryptocurrencies, among a variety of others (https://ibn.fm/9s0F0). For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• The VBF acquisition is expected to be accretive to MCOA’s revenue and EBITDA forecasts for 2022
• The company launched new subsidiaries in Brazil and Uruguay to distribute its hempsmart premium product line in Latin America
• The company recently launched a new social media marketing campaign via Instagram, Twitter, TikTok, etc.
• The global legal marijuana market was valued at $9.1 billion in 2020 and is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028, putting the market value at roughly $30 billion by 2025

Marijuana Company of America (OTC: MCOA) operates and invests in the cannabis sector directly. The company’s diverse operations include cDistro, one of the THC, hemp & CBD cannabis industries’ fastest growing distribution companies; hempsmart(TM), a premium CBD company; and VBF Brands Inc., a cannabis nursery cultivation facility in Salinas, California, that is a cultivator and distributor utilizing its own growing systems to produce desirable cannabis clones. MCOA continues to grow its business while remaining fiscally conscious and further establishing itself in the legalized cannabis THC, hemp & CBD industries by offering unique exposure to the global cannabidiol sector. The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners. Marijuana Company of America offers investors the opportunity to be at the forefront of innovation in the legal cannabis and industrial hemp industries. During the summer of 2021, the U.S. witnessed the introduction of the most comprehensive cannabis reform ever proposed at the federal level, as well as ongoing state-level liberalization. The investments MCOA has made will position the company to drive the expected strongest revenue growth in the company’s history. MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and partners with the best opportunities for rapid growth. It is MCOA’s attention to detail in producing premium products and adhering to the best business practices that distinguish it among the leaders of cannabis products in the global marketplace. MCOA is building a portfolio of investments and joint ventures that represent the highest integrity and professionalism in the legal cannabis and industrial hemp markets. MCOA is a model for entrepreneurs and businesses that share its common goals and philosophies of not only creating value for investors but also creating an environment for businesses to improve the quality of life of customers through sustainable alternatives to many products currently on the market. Partnerships and Investments MCOA has partnered with and invested in a portfolio of companies operating in the cannabis sector. These include: Cannabis Global Inc. Cannabis Global (OTC: CBGL) is an emerging force in the cannabis marketplace with growing product and intellectual property portfolios. CBGL is marketing and producing Comply Bag(TM), an innovative solution for cannabis storage, transport, and tracking, and is also the developer and marketer of the Hemp You Can Feel(TM) brand. Eco Innovation Group Inc. Eco Innovation Group (OTC: ECOX) works with inventors and other professionals to nurture and catalyze the most innovative and impactful products and services and deliver those innovations to market. ECOX is dedicated to developing and commercializing successful products. MCOA’s investment supports Eco Innovation’s cutting-edge extraction technology. ECOX’s extraction processes utilize a proprietary formulation to extract valuable bioactive compounds from cannabidiol (“CBD”) combined with plant-based materials to create a fluid and cost-effective output. Together, both companies are positioned to identify and accelerate the development of new varieties of hemp-based products and distribute them worldwide. Natural Plant Extract MCOA owns a direct investment interest in Natural Plant Extract (“NPE”), which operates a licensed cannabis manufacturing and distribution business in Lynwood, California. NPE holds a Type 7 California manufacturing and distribution license, allowing for cannabis product distribution anywhere in the State of California. Wholly Owned Subsidiaries hempsmart(TM) hempsmart(TM) is a CBD company focused on creating and promoting the most effective, best tasting, and highest quality products on the market. In 2021, hempsmart expanded into the global marketplace and announced a rebrand that featured a fresh take on its packaging and a social media campaign to engage customers via Instagram, Twitter, TikTok, and more, which has now generated a new loyal group of followers. hempsmart premier products include its Smart Drops (CBD Drops), Neuro Smart (Patented Brain Pills), and Smart Cream (Pain Cream) brands. These organic, plant-based products help to manage anxiety, pain and insomnia, without the inclusion of THC. cDistro cDistro distributes CBD brands, along with smoke and vape shop-related products, to wholesalers, c-stores, specialty retailers, and consumers in North America. cDistro was chosen as one of the first to distribute Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family. The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion’s mane, chaga, reishi and turkey tail, that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. VBF Brands Inc. MCOA recently completed the acquisition of VBF Brands Inc., a fully licensed marijuana cultivator and distributor based in Salinas, California. VBF utilizes its own growing systems to produce desirable cannabis clones that are designed to assist growers by reducing uncertainty and enhancing the likelihood of a successful cultivation harvest. Cannabis clones carry the exact same genetic potential as their mother plants and have similar cannabinoid and terpene profiles when grown properly. This subsidiary will immediately work toward increasing production at its Salinas facility, which also offers exponential growth potential with other nearby properties that MCOA has an option to participate in as part of the acquisition. Market Outlook Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will increase opportunities for this market. According to a Grand View Research report, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028. That would put the market value at roughly $30 billion by 2025. The report cites the growing number of countries that are legalizing cannabis as a driver for surging demand. It also points out the use of medical marijuana for various ailments is gaining momentum worldwide. Medical marijuana is prescribed for patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s and other neurological disorders. The demand for cannabis oil is also increasing rapidly, especially among countries with legalized medical marijuana. Management Team Jesus Quintero is the CEO and Chairman of MCOA. From January 2013 to September 2014, he was the Chief Financial Officer of Brazil Interactive Media Inc. Since 2011, he has served as a financial consultant to several multimillion-dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance and held senior finance positions with Avnet Inc., Latin Node Inc., Globetel Communications Corp., and Telefonica of Spain. His prior experience also includes positions at Price Waterhouse and Deloitte & Touche. He holds a B.S. in Accounting from St. John’s University and is a certified public accountant. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com. NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• PlantX Life is the digital face of the plant-based community that offers over 5,000 products through its ever-expanding marketplace
• The company is also committed to educating and empowering people interested in the plant-based lifestyle
• PlantX regularly updates its website with blogs and articles about living a holistic      plant-based lifestyle
• Through its YouTube channel, the company uploads recipe videos as well as informative videos in which health coaches share tips to help viewers adopt/lead a plant-based lifestyle

A plant-based diet is more sustainable. At the same time, it offers numerous health benefits to virtually all age groups. For adolescents, in particular, research suggests that they can obtain health benefits such as improved cardiovascular health and enhanced weight control by simply embracing a plant-based diet. However, the independence that comes with being adolescents means that this group makes fewer healthy food choices. Before the publication of a 2021 peer-reviewed journal article, titled “Adolescent’s Willingness to Adopt a More Plant-Based Diet: A Theory-Based Interview Study,” it was previously unclear what factors promote or hinder adolescents’ intention to take up plant-based dietary habits. Nonetheless, the investigation now offers insight into these motivations as captured in the study’s findings and conclusion (https://ibn.fm/oEEdD). Firstly, participants noted that they lacked the skills to prepare plant-based meals despite expressing confidence in being able to consume such a diet for a definite period. Secondly, their unwillingness stemmed from the perception that plant-based food options had poor taste. Therefore, the study concluded that education on the plant-based diet with the aim of increasing awareness of the benefits and equipping individuals with skills to procure or prepare plant-based meals could increase plant-based food familiarity and knowledge. Though the study focused on adolescents, the conclusion is being implemented far and wide. For instance, colleges and universities are introducing official certification programs in plant-based nutrition, including even Ph.D. level coursework (https://ibn.fm/z057m). As the digital face of the plant-based community, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has not been left behind. Through YouTube videos, a weekly podcast, blog articles, and other educational resources, PlantX is playing a vital role in increasing knowledge of plant-based lifestyle, products, recipes, and more, thus eliminating the barriers of entry, some of which the 2021 study identified. The company’s YouTube Channel, for instance, contains recipe videos showing the preparation diverse plant-based foods from different parts of the world. So far, PlantX has showcased Bolognese, Mexican, and Thai dishes that are both easy to prepare, thanks to detailed and clear cooking instructions, and tasty. The channel also contains videos wherein health coaches and nutritionists offer tips and guidance to help viewers adopt and lead a plant-based lifestyle. In addition, PlantX regularly updates its website with new blogs and articles about living a simple plant-based life. Through these resources, the company avails education materials that not only teach readers the benefits of a plant-based lifestyle but also offer tips intended to guide people following this way of life. Notably, these resources demonstrate PlantX’s commitment to educate and empower people following a plant-based or flexitarian lifestyle, as well as those interested in these dietary habits. PlantX believes that learning the benefits of a plant-based lifestyle is only the beginning, further holding that such a lifestyle extends beyond just a diet. “It’s a way to connect to nature, to each other, and work toward a cruelty-free future for everyone on the planet,” reads the company’s website. In concert with the education resources available on its website and YouTube channel, PlantX also offers over 5,000 plant-based products through an ever-expanding marketplace for all things wellness and health. First launched in early 2020, PlantX represents the one-stop shop for all things plant-based. With an offering that includes meal deliveries, plants, and consumer plant-based goods from new and established brands, the company is building a community of like-minded consumers and offering education. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Tingo is committed to becoming truly Pan-African Agri-Fintech company with a global reach
• Founded two decades ago, Tingo is Africa’s market leader focused on agriculture and related financial services with over $600 million annual revenues and nearly 10 million users
• As a profitable company focused on making a positive impact on people in rural communities, Tingo aims to unite market growth potential with opportunities to contribute to a social change across Africa

With a vision to empower societies and create social upliftment in rural African communities by building digitally inclusive ecosystems and promoting financial inclusion, Tingo (OTCQB: IWBB) is forging ahead committed to becoming a Pan-African Agri-Fintech company with a global reach. Established in 2001 by Dozy Mmobuosi, CEO and co-founder, to bring mobile technology and fintech solutions to the unbanked rural areas in Nigeria, Tingo today is the leading company focused on agriculture across Africa with over $600 million annual revenues and nearly 10 million subscribers. Mmobuosi, a Ph.D. holder with a spirit of a serial entrepreneur is confident that the company is well on its way to becoming the continent’s leading agri-fintech player (https://ibn.fm/Tyey2). Recognizing that achieving the United Nations Sustainable Development goals—adopted as the company’s guiding principles—is closely connected with strategies that build economic growth, Tingo aims to connect players across the agricultural value chain, from farmers to packaging and logistic partners to consumers looking to buy fresh produce at the best prices. With this goal in mind, the company has centered its operations around these core business segments—device as a service (mobile phone leasing, mobile voice and data services), the Nwassa Marketplace Platform, and Tingo Pay. Through this vertically integrated business model, Tingo provides farmers with communication tools and access to market and financial inclusion. First, Tingo supplies farmers with a Tingo-manufactured handset, using Tingo’s mobile data and voice services. Farmers can then access the Nwassa platform, Tingo’s proprietary digital platform for agriculture, which allows everyone to engage in agribusiness anytime and on the go. Finally, there is Tingo Pay, the in-house payment platform built specifically to serve actors on the Nwassa platform and power the African agricultural value chain. With financial services such as mobile wallets, payment processing and access to specialist lenders, insurers, and pension products, Tingo Pay helps African farmers with financial inclusion. The platform processes more than 500,000 transactions daily with a value of over $8 million per day (https://ibn.fm/veq7t). Still, Tingo is not stopping there. The company is forging ahead with ambitious plans as it is positioning the platform to broaden the market reach by making Tingo Pay available to the general public. The company also intends to roll out a blockchain-based solution to enable frictionless trade across borders in Africa. With the goal to become a truly Pan-African company with a global reach, Tingo strives to build a company that can potentially make a difference for the continent by providing a complete digital ecosystem for agribusiness, a critical component of Africa’s economy. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at https://ibn.fm/IWBB

Date: OCTOBER 28-30, 2022 Venue: Chicago With the recent completion of their jumbo event in Chicago, the USA CBD Expo team has rebranded their event series as ‘Alternative Products Expo’. Chicago’s USA CBD Expo, the country’s biggest CBD event and covering the largest assortment of hemp and CBD goods, imparted critical knowledge to niche company owners on how to reach new consumers and expand their market share. Over the past few years, the industry’s top buyers, investors, and wholesalers, have visited the USA CBD events at:

• Miami Beach Convention Center, Miami – August 2-4, 2019
• Las Vegas Convention Center, Vegas – February 13-15, 2020
• Plaza Mayor, Medellín, Colombia – February 22-23, 2020
• Georgia World Congress Center, Atlanta – June 11-13, 2021
• McCormick Place, Chicago – October 28-30, 2021

The recent USA CBD Expo event, held at Chicago’s McCormick Place (America’s largest convention hall), featured more than 500 prominent industry names. Event Highlights The event was unlike what Chicago had ever seen. With influences from previous events held at Atlanta and Miami, USA CBD Expo strove to increase the positive perception surrounding CBD and CBD products!

• It was a 3-day event with one B2B-only day which focused on sales
• The event saw sales including but not limited to hemp-derived products, semi-synthetic extracts, functional beverages, non-psychoactive mushrooms and more
• The event was held at the McCormick Place in Chicago (biggest convention hall in America)
• 50+ Industry Expert Speaker Panels visited the event and completed the event
• The 300+ vendor sales with the best 500+ industry brands at the event saw approximately 1.2 million dollars in sales which has been the largest of any event that has been covered by CBD Expo
• Although this event was for ages 21+ only, the effects of CBD products on children were also examined
• The USA CBD Expo has transitioned to Alternative Products Expo
• Alternative Products Expo is a B2B and B2C networking event for disrupting industries including hemp-derived products, semi-synthetic extracts, functional beverages, non-psychoactive mushrooms, delta8, kratom, nicotine alternatives, nutraceuticals, and many others
• The Chicago 2021 Expo broadened its horizons to include items that are not a part of the cannabis industry (Delta 8, psilocybin, nutraceuticals, functional beverages, etc.)

Expert speakers shared their insights with participants and attendees on topics such as business, science, and law throughout the three-day event. According to a Gallup poll, every seventh American now consumes CBD in some form, and the speakers examined the causes for this growth in the multibillion-dollar sector. At the Chicago event, interested consumers:

• Met nearly 400 vendors who are bringing the top brands in the industry!
• Learned from more than 50 industry experts who will share their experience and perspectives!
• Found out about one-of-a-kind possibilities to buy retail or wholesale items at show-only prices.
• Found niche products that their company could market to a wider audience.

Not only did the USA CBD Expo Chicago showcase a varied range of fascinating presentations, but it also provided much-needed practical answers. This conference brought together cannabinoid scientists and professionals from all around the world to network and innovate. Attendees could choose from a variety of thought-provoking panels to learn about the industry’s cutting-edge technologies. Under the supervision of CBD industry professionals, they updated their knowledge of regulation and compliance, increased sales, and fine-tuned their marketing skills. Future Events to Look Out For

• Fort Lauderdale Alternative Products Expo 2022, Chicago 2022-Featuring all of the cutting-edge products and services that are upending established markets. All of the bells and whistles of a CBD Expo and much more!
• BizCann Expo New York 2022, Medellin 2022- For those wishing to expand their enterprises by entering or adding the cannabis industry to their operations

For more information regarding the USA CBD EXPO Chicago Event, kindly visit https://altproexpo.com/

• Avricore has been focused on the development of a network of POC analyzers running on its HealthTab software platform in community pharmacy
• So far, its platform can check up to 27 health markers, screen diabetes, and test Covid-19
• With multiple revenue streams, a key selling point for Avricore remains its commitment to patient health and convenience
• Through its innovations and forging the right partnerships, Avricore is getting closer to consumers and presenting even more possibilities for its HealthTab platform

At the start of 2021, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) set out to achieve four main milestones- the Abbott agreement, the Shoppers agreement, the HeathTab(TM) Pilot, and the HealthTab Rollout. As of May 31, 2021, the company had already signed a deal with Abbott to expand the distribution of its Afnion 2 analyzer in pharmacies, while on June 3, Shoppers signed an agreement to stock HealthTab for diabetes screening in 11 different locations, bringing its services closer to patients (https://ibn.fm/vFITf). Since its inception, Avricore has been driven by the development of a network of point-of-care (“POC”) analyzers that run on the company’s HealthTab software in community pharmacies, workplaces, and rural areas (https://ibn.fm/TrrRA). The company has recognized an opportunity and capitalizes on established consumer trends, technology advancements, health policy, and industry changes, to solve a business headache while also meeting a significant market opportunity. All this is built on the company’s HealthTab platform. As it works towards the HealthTab rollout, Avricore is implementing its decisions from a point of information and knowing its platform’s potential. So far, HealthTab can check up to 27 health markers, screen diabetes, and conduct rapid Covid-19 testing. It also offers convenience, with analyses taking less than 10 minutes. Most importantly, it is a platform that prioritizes safety and confidentiality, given that the consumer is in control of their data, ultimately choosing whom they can share it with (https://ibn.fm/FTSN1). Avricore has several revenue streams, including equipment leasing, data, consumables, screening tests, and application programming interface (“API”) integration. However, its primary selling point is its commitment to patients, primarily through its HealthTab platform. “What HealthTab does is it creates a space where a patient can take direct agency over their health. They can walk into any pharmacy, they can ask that question, and they can get information that they can act on now,” noted Hector Bremner, the chief executive officer (“CEO”) of Avricore (https://ibn.fm/dBYXP). The milestones achieved with HealthTab so far are significant. More so, they highlight the endless possibilities that the platform has regarding the diagnosis of various chronic diseases, bacteria, and viruses. This is further evidenced by the company’s recent moves and executive decisions. Its expansion of POC medical condition testing to Canada’s west coast and the planned HealthTab rollout are a testament to what the platform is capable of, Avricore’s potential going forward, and the company’s commitment to patients. Avricore is at the forefront in the POC diagnostics space and remains committed to becoming the world’s largest health diagnostics company. With consistent innovation and forging the right partnerships with strategic players in the healthcare sector, Avricore is getting closer to the consumers and presenting even more possibilities with its HealthTab platform. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF